第 1 到 163 筆結果,共 163 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2011 | Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells | Chen K.-F.; Chen H.-L.; Tai W.-T.; Feng W.-C.; CHIH-HUNG HSU ; PEI-JER CHEN ; ANN-LII CHENG | Journal of Pharmacology and Experimental Therapeutics | 260 | 254 | |
2 | 2008 | Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma | CHIA-CHI LIN ; YEONG-SHIAU PU ; CHIH-HUNG HSU ; Keng H.-Y.; ANN-LII CHENG ; CHIH-HSIN YANG | Urologic Oncology: Seminars and Original Investigations | 8 | 7 | |
3 | 2020 | Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: A long-awaited breakthrough finally arrives | HUNG-YANG KUO ; JHE-CYUAN GUO ; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 14 | 15 | |
4 | 2006 | The application of aquaplast thermoplastic as a bolus material in the radiotherapy of a patient with classic Kaposi's sarcoma at the lower extremity | Huang K.-M.; CHIH-HUNG HSU ; Jeng S.-C.; Ting L.-L.; CHIA-HSIEN CHENG ; Huang W.-T. | Anticancer Research | 9 | 8 | |
5 | 2007 | Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial | CHIA-CHI LIN ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HSIN YANG | Investigational New Drugs | 104 | 103 | |
6 | 2022 | Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma | Lee, Jan-Mou; Hung, Yi-Ping; Chou, Kai-Yuan; Lee, Cheng-Yun; Lin, Shian-Ren; Tsai, Ya-Han; Lai, Wan-Yu; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; Chao, Yee | Frontiers in medicine | 2 | 2 | |
7 | 2022 | Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma | YU-YUN SHAO ; HUNG-YANG KUO ; YUNG-MING JENG ; YAO-MING WU ; HSIU-PO WANG ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | BMC cancer | 3 | 3 | |
8 | 2009 | Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy | Feng-Ming Hsu ; Lee Y.-C.; JANG-MING LEE ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YU-CHIEH TSAI ; Wu J.-K.; CHIA-HSIEN CHENG | Annals of Surgical Oncology | 33 | 32 | |
9 | 2020 | Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study | Lee M.S.; Ryoo B.-Y.; CHIH-HUNG HSU ; Numata K.; Stein S.; Verret W.; Hack S.P.; Spahn J.; Liu B.; Abdullah H.; Wang Y.; He A.R.; Lee K.-H.; Bang Y.-J.; Bendell J.; Chao Y.; Chen J.-S.; Chung H.C.; Davis S.L.; Dev A.; Gane E.; George B.; He A.R.; Hochster H.; CHIUN HSU ; Ikeda M.; Lee J.; Lee M.; Mahipal A.; Manji G.; Morimoto M.; Numata K.; Pishvaian M.; Qin S.; Ryan D.; Ryoo B.-Y.; Sasahira N.; Stein S.; Strickler J.; Tebbutt N. | The Lancet Oncology | 353 | 312 | |
10 | 2009 | The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma | ZHONG-ZHE LIN ; Hsu H.-C.; CHIH-HUNG HSU ; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; SUNG-HSIN KUO ; CHIUN HSU ; Hu F.-C.; YUNG-MING JENG ; Chung Y.; ANN-LII CHENG | Journal of Hepatology | 38 | 39 | |
11 | 2022 | B Cells in Tumor Microenvironment Associated With The Clinical Benefit to Programmed Cell Death Protein-1 Blockade Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | JHE-CYUAN GUO ; Hsu, Chia-Lang; YEN-LIN HUANG ; CHIA-CHI LIN ; TA-CHEN HUANG ; Wu, I-Chen; Lin, Chen-Yuan; Lien, Ming-Yu; HUNG-YANG KUO ; ANN-LII CHENG ; CHIH-HUNG HSU | Frontiers in oncology | 2 | 1 | |
12 | 2022 | Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety | YU-YUN SHAO ; Feng Y.-H.; Yen C.-J.; Yang T.-S.; YING-CHUN SHEN ; Chao Y.; Chen J.-S.; Su C.-Y.; Chen W.-J.; Hsiang H.-L.; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 3 | 4 | |
13 | 2013 | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | CHIH-HUNG HSU ; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN ; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU ; ANN-LII CHENG | Oncology (Switzerland) | 40 | 41 | |
14 | 2009 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway | Chen K.-F.; Yeh P.-Y.; CHIUN HSU ; CHIH-HUNG HSU ; YEN-SHEN LU ; Hsieh H.-P.; PEI-JER CHEN ; ANN-LII CHENG | Journal of Biological Chemistry | 89 | 84 | |
15 | 2013 | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study | Johnson P.J.; Qin S.; Park J.-W.; Poon R.T.P.; Raoul J.-L.; Philip P.A.; CHIH-HUNG HSU ; Hu T.-H.; Heo J.; Xu J.; Lu L.; Chao Y.; Boucher E.; Han K.-H.; Paik S.-W.; Robles-Aviña J.; Kudo M.; Yan L.; Sobhonslidsuk A.; Komov D.; Decaens T.; Tak W.-Y.; Jeng L.-B.; Liu D.; Ezzeddine R.; Walters I.; ANN-LII CHENG | Journal of Clinical Oncology | 618 | 595 | |
16 | 2006 | Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy | DA-LIANG OU ; Chen C.-L.; Lin S.B.; CHIH-HUNG HSU ; LIANG-IN LIN | Journal of Pathology | 61 | 52 | |
17 | 2002 | The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells | Hergenhahn M.; Soto U.; Weninger A.; Polack A.; CHIH-HUNG HSU ; ANN-LII CHENG ; Rösl F. | Molecular Carcinogenesis | 70 | 61 | |
18 | 2014 | Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy | LI-CHUN LU ; YU-YUN SHAO ; Chan S.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | 10 | |
19 | 1993 | Cloning and expression of the gene encoding Acacia confusa trypsin inhibitor that is active without post-translational proteolysis | CHIH-HUNG HSU ; Ming-Chih L.; Ming-Tay L.; Jung-Yaw L. | Gene | 15 | 14 | |
20 | 2001 | Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma | CHIH-HUNG HSU ; Chen J.; Wu C.-Y.; ANN-LII CHENG ; YEONG-SHIAU PU | Anticancer Research | 27 | 24 | |
21 | 2002 | Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma | Huang C.-L.; ZHONG-ZHE LIN ; Su I.-J.; Chao T.-Y.; HWEI-FANG TIEN ; Chang M.-C.; Huang M.-C.; Kao W.-Y.; JIH-LUH TANG ; KUN-HUEI YEH ; Wang C.-H.; CHIH-HUNG HSU ; Liu M.-Y.; ANN-LII CHENG | Leukemia and Lymphoma | 9 | 5 | |
22 | 2010 | Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma | Chiang C.-T.; Yeh P.-Y.; Gao M.; Chen C.-W.; Yeh L.-C.; Feng W.-C.; SUNG-HSIN KUO ; CHIH-HUNG HSU ; YEN-SHEN LU ; ANN-LII CHENG | Cancer Letters | 19 | 19 | |
23 | 2012 | Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma | Yen T.-J.; Chung C.-S.; YEN-WEN WU ; RUOH-FANG YEN ; MEI-FANG CHENG ; JANG-MING LEE ; CHIH-HUNG HSU ; YIH-LEONG CHANG ; HSIU-PO WANG | Diseases of the Esophagus | 33 | 30 | |
24 | 2007 | Comparison of the phosphorylation of 4′-ethynyl 2′,3′- dihydro3′-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs | CHIH-HUNG HSU ; Hu R.; Dutschman G.E.; Yang G.; Krishnan P.; Tanaka H.; Baba M.; Cheng Y.-C. | Antimicrobial Agents and Chemotherapy | 14 | 13 | |
25 | 2006 | Complete response of urothelial carcinoma to chemotherapy in renal allograft recipients: A two-case study | CHIA-CHI LIN ; CHIH-HUNG HSU ; YEONG-SHIAU PU | Anticancer Research | 0 | 0 | |
26 | 1999 | Concurrent chemoradiotherapy for locally advanced esophageal cancer - A pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil | CHIH-HUNG HSU ; KUN-HUEI YEH ; Lui L.T.; Lee Y.-C.; Bu C.-F.; HSIU-PO WANG ; Lin J.-T.; ANN-LII CHENG | Anticancer Research | 29 | 26 | |
27 | 2007 | Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; JANG-MING LEE ; KUN-HUEI YEH ; CHIH-HSIN YANG ; Lin J.-T.; ANN-LII CHENG ; Lee Y.-C. | Annals of Oncology | 39 | 36 | |
28 | 2000 | Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis | Chuang S.E.; Kuo M.L.; CHIH-HUNG HSU ; Chen C.R.; Lin J.K.; Lai G.M.; CHANG-YAO HSIEH ; ANN-LII CHENG | Carcinogenesis | 240 | 210 | |
29 | 2022 | Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma | YU-YUN SHAO ; Hsu, Hung-Wei; Wo, Rita Robin; Wang, Han-Yu; ANN-LII CHENG ; CHIH-HUNG HSU | Oncology | 3 | 3 | |
30 | 2022 | Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma | JHE-CYUAN GUO ; CHIA-CHI LIN ; Hsu, Chia-Lang; TA-CHEN HUANG ; HUNG-YANG KUO ; Lin, Chen-Yuan; Lien, Ming-Yu; ANN-LII CHENG ; CHIH-HUNG HSU | Esophagus : official journal of the Japan Esophageal Society | 0 | 0 | |
31 | 2012 | Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma | Shau W.-Y.; YU-YUN SHAO ; Yeh Y.-C.; ZHONG-ZHE LIN ; Kuo R.; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG ; Lai M.-S. | Oncologist | 32 | 32 | |
32 | 2019 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | LI-CHUN LU ; CHIUN HSU ; YU-YUN SHAO ; Chao Y.; Yen C.-J.; I-LUN SHIH ; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen ; JHE-CYUAN GUO ; TSUNG-HAO LIU ; CHIH-HUNG HSU ; ANN-LII CHENG | Liver Cancer | 46 | 44 | |
33 | 2008 | Disseminated peritoneal leiomyomatosis responds to systemic chemotherapy | Lin Y.-C.; LING-HUNG WEI ; CHIA-TUNG SHUN ; ANN-LII CHENG ; CHIH-HUNG HSU | Oncology | 28 | 20 | |
34 | 2012 | Dissimilar immunohistochemical expression of ERK and AKT between paired biopsy and hepatectomy tissues of hepatocellular carcinoma | YU-YUN SHAO ; Chen C.-L.; MING-CHIH HO ; Huang C.-C.; Tu H.-C.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 9 | 10 | |
35 | 2004 | Doxorubicin activates hepatitis B virus (HBV) replication in HBV-harboring hepatoblastoma cells. A possible novel mechanism of HBV reactivation in HBV carriers receiving systemic chemotherapy | CHIH-HUNG HSU ; Hsu H.-C.; Chen H.-L.; Gao M.; Yeh P.-Y.; PEI-JER CHEN ; ANN-LII CHENG | Anticancer Research | 47 | 41 | |
36 | 2021 | Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma | BANG-BIN CHEN ; YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Diagnostics (Basel, Switzerland) | 7 | 7 | |
37 | 2011 | Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil | CHAO-YU HSU ; Ying-Chun Shen ; CHIH-WEI YU ; CHIUN HSU ; Hu F.-C.; CHIH-HUNG HSU ; BANG-BIN CHEN ; Wei S.-Y.; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | Journal of Hepatology | 106 | 100 | |
38 | 2010 | Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer | 141 | 148 | |
39 | 2019 | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; CHIUN HSU ; LI-CHUN LU ; YING-CHUN SHEN ; ZHONG-ZHE LIN ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver International | 56 | 58 | |
40 | 2021 | Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials | BANG-BIN CHEN ; ZHONG-ZHE LIN ; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Cancers | 4 | 3 | |
41 | 2017 | Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma | BANG-BIN CHEN ; CHAO-YU HSU ; CHIH-WEI YU ; PO-CHIN LIANG ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | European Radiology | 15 | 17 | |
42 | 2020 | Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies | Yen C.-J.; Kudo M.; Lim H.-Y.; CHIH-HUNG HSU ; Vogel A.; Brandi G.; Cheng R.; Nitu I.S.; Abada P.; Hsu Y.; Zhu A.X.; Kang Y.-K. | Liver Cancer | 12 | 10 | |
43 | 2010 | Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Yang T.-S.; CHIUN HSU ; Toh H.C.; Epstein R.J.; Hsiao L.-T.; PEI-JER CHEN ; ZHONG-ZHE LIN ; Chao T.-Y.; ANN-LII CHENG | British Journal of Cancer | 114 | 112 | |
44 | 2012 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Lee, Kuan-Der; Hsiao, Chi-Huang; YEN-SHEN LU ; Huang, Chien-Chung; YING-CHUN SHEN ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 26 | 25 | |
45 | 2021 | Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma | YU-YUN SHAO ; Sun, Nai-Yun; YUNG-MING JENG ; YAO-MING WU ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | Cells | 3 | 2 | |
46 | 2023 | Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: Implications of positive phase III trials in advanced and resected esophageal cancer | HUNG-YANG KUO ; JHE-CYUAN GUO ; CHIH-HUNG HSU | Journal of the Formosan Medical Association = Taiwan yi zhi | 2 | 2 | |
47 | 2023 | Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study | Pant, Shubham; Schuler, Martin; Iyer, Gopa; Witt, Olaf; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Reardon, David A; Massard, Christophe; Minchom, Anna; Lugowska, Iwona; Carranza, Omar; Arnold, Dirk; Gutierrez, Martin; Winter, Helen; Stuyckens, Kim; Crow, Lauren; Najmi, Saltanat; Hammond, Constance; Thomas, Shibu; Santiago-Walker, Ademi; Triantos, Spyros; Sweiti, Hussein; Loriot, Yohann; CHIH-HUNG HSU | The Lancet. Oncology | 18 | ||
48 | 2007 | Esophageal adenocarcinoma arising from Barrett's epithelium in Taiwan | CHIA-HUNG TU ; Lee C.-T.; Perng D.-S.; Chang C.-C.; CHIH-HUNG HSU ; YI-CHIA LEE | Journal of the Formosan Medical Association | 7 | 5 | |
49 | 2022 | Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study | Chen, Ching-Tso; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | Anticancer research | 0 | 0 | |
50 | 2012 | Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy | ZHONG-ZHE LIN ; CHIUN HSU ; Hu F.-C.; YU-YUN SHAO ; DWANG-YING CHANG ; CHIH-HSIN YANG ; RUEY-LONG HONG ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncologist | 8 | 10 | |
51 | 2007 | Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; Keng H.-Y.; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | Anti-Cancer Drugs | 32 | 29 | |
52 | 2013 | The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; Chang Y.-L.; Huang C.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology (Switzerland) | 5 | 5 | |
53 | 2017 | Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells | YU-YUN SHAO ; MIN-SHU HSIEH ; Wang, Han Yu; Li, Yong Shi; Lin, Hang; Hsu, Hung Wei; Huang, Chung Yi; CHIH-HUNG HSU ; ANN-LII CHENG | Oncotarget | 12 | 9 | |
54 | 2011 | High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy | YU-YUN SHAO ; ZHONG-ZHE LIN ; Chen T.-J.; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 17 | 17 | |
55 | 2017 | High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; ANN-LII CHENG ; CHIH-HUNG HSU | Japanese Journal of Clinical Oncology | 34 | 31 | |
56 | 2015 | High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib | Lin T.-H.; YU-YUN SHAO ; Chan S.-Y.; Huang C.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Clinical Cancer Research | 78 | 78 | |
57 | 2002 | High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection | JIN-TUNG LIANG ; KUO-CHIN HUANG ; HONG-SHIEE LAI ; PO-HUANG LEE ; Cheng Y.-M.; Hsu H.-C.; ANN-LII CHENG ; CHIH-HUNG HSU ; KUN-HUEI YEH ; Wang S.-M.; Tang C.; KING-JEN CHANG | International Journal of Cancer | 109 | 98 | |
58 | 2013 | Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma | LI-CHUN LU ; YU-YUN SHAO ; Kuo R.N.C.; ZHONG-ZHE LIN ; Yeh Y.-C.; Shau W.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG ; Lai M.-S. | Cancer | 11 | 11 | |
59 | 2022 | ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis | LI-CHUN LU ; Deantonio, Cecilia; Palu, Cintia C; Lee, Yi-Hsuan; Mitchell, Laura S; Cowan, Marianne; Corser, Matthew; Sherry, Lorcan; ANN-LII CHENG ; Quaratino, Sonia; YU-YUN SHAO ; Sainson, Richard C A; CHIH-HUNG HSU | Oncology (Switzerland) | 0 | 0 | |
60 | 2011 | Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; PEI-JER CHEN ; ZHONG-ZHE LIN ; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | ||
61 | 2021 | Impact of expanded strong opioid availability on opioid prescription patterns in patients with cancer: A population-wide cohort study in Taiwan | Wu T.-C.; CHIH-HUNG HSU ; WEI-ZEN SUN ; Chen H.-M.; CHIH-PENG LIN ; YU-YUN SHAO | The Lancet Regional Health - Western Pacific | 3 | 3 | |
62 | 2008 | Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study | FENG-MING HSU ; CHIA-CHI LIN ; JANG-MING LEE ; YIH-LEONG CHANG ; CHIH-HUNG HSU ; YU-CHIEH TSAI ; Lee Y.-C.; CHIA-HSIEN CHENG | Journal of Surgical Oncology | 32 | 29 | |
63 | 2019 | Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment | SHAO-LUN LU ; Feng-Ming Hsu ; CHIAO-LING TSAI ; JANG-MING LEE ; PEI-MING HUANG ; CHIH-HUNG HSU ; CHIA-CHI LIN ; YIH-LEONG CHANG ; MIN-SHU HSIEH ; CHIA-HSIEN CHENG | European Journal of Surgical Oncology | 9 | 7 | |
64 | 2019 | Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment | LI-CHUN LU ; Lee, Yi Hsuan; Chang, Chun Jung; CHIA-TUNG SHUN ; Fang, Chih Yeu; YU-YUN SHAO ; TSUNG-HAO LIU ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver Cancer | 45 | 41 | |
65 | 2011 | Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy | YU-YUN SHAO ; LI-CHUN LU ; ANN-LII CHENG ; CHIH-HUNG HSU | Oncologist | 34 | 28 | |
66 | 2011 | Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: A Taiwan cooperative oncology group phase II study | Ch'Ang H.-J.; Lin Y.-L.; HSIU-PO WANG ; Chiu Y.-F.; MING-CHU CHANG ; CHIH-HUNG HSU ; YU-WEN TIEN ; Chen J.-S.; Hsieh R.-K.; Lin P.-W.; Shan Y.-S.; ANN-LII CHENG ; Chang J.-Y.; Whang-Peng J.; Hwang T.-L.; Chen L.-T. | International Journal of Radiation Oncology Biology Physics | 19 | 17 | |
67 | 2009 | Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; Feng-Ming Hsu ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | International Journal of Radiation Oncology Biology Physics | 27 | 22 | |
68 | 2002 | Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin | CHIH-HUNG HSU ; Hergenhahn M.; Chuang S.-E.; Yeh P.-Y.; Wu T.-C.; Gao M.; ANN-LII CHENG | Anticancer Research | 15 | 13 | |
69 | 2011 | Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials | SHIH-HUNG YANG ; Kuo Y.-H.; YU-WEN TIEN ; CHIUN HSU ; CHIH-HUNG HSU ; SUNG-HSIN KUO ; ANN-LII CHENG | Oncology | 13 | 13 | |
70 | 2016 | Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma | Lin H.-H.; Feng W.-C.; LI-CHUN LU ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer letters | 36 | 39 | |
71 | 2005 | Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro | CHIH-HUNG HSU ; Gao M.; Chen C.-L.; Yeh P.-Y.; ANN-LII CHENG | Oncology | 39 | 37 | |
72 | 2015 | Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer | Yeh C.-C.; CHIH-HUNG HSU ; YU-YUN SHAO ; Ho W.-C.; MONG-HSUN TSAI ; Feng W.-C.; LU-PING CHOW | Molecular and Cellular Proteomics | 55 | 50 | |
73 | 2008 | Intraperitoneal metastasis of hepatocellular carcinoma after spontaneous rupture: A case report | Hung M.-C.; Wu H.-S.; Lee Y.-T.; CHIH-HUNG HSU ; Chou D.-A.; Huang M.-H. | World Journal of Gastroenterology | 33 | 30 | |
74 | 2015 | A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer | Chen J.S.; CHIH-HUNG HSU ; Chiang N.J.; Tsai C.S.; Tsou H.H.; Huang S.F.; Bai L.Y.; Chang I.C.; Shiah H.S.; Ho C.L.; Yen C.J.; Lee K.D.; Chiu C.F.; Rau K.M.; Yu M.S.; Yang Y.; Hsieh R.K.; Chang J.Y.; Shan Y.S.; Chao Y.; Chen L.-T.; Chin Y.-H.; Chung T.-R.; Yu W.-L.; Lee M.-H.; Lin L.-F.; Lin P.-C.; Wu Y.-L.; Wang H.-L.; Lu L.-J.; Chen S.-Y.; Wu C.-C.; Wei T.-C.; on behalf of the Taiwan Cooperative Oncology Group | Annals of Oncology | 131 | 115 | |
75 | 2011 | Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001 | SUNG-HSIN KUO ; CHIH-HUNG HSU ; Chen L.-T.; YEN-SHEN LU ; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; KUN-HUEI YEH ; ANN-LII CHENG | European Journal of Cancer | 17 | 17 | |
76 | 2017 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy | YU-YUN SHAO ; BANG-BIN CHEN ; DA-LIANG OU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; Wang, M. J.; ANN-LII CHENG ; CHIUN HSU | Alimentary Pharmacology and Therapeutics | 10 | 8 | |
77 | 2021 | Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy | YING-CHUN SHEN ; Yeh C.-P.; YUNG-MING JENG ; CHIUN HSU ; CHIH-HUNG HSU ; ZHONG-ZHE LIN ; YU-YUN SHAO ; LI-CHUN LU ; TSUNG-HAO LIU ; CHIEN-HUNG CHEN ; ANN-LII CHENG | Cancers | 2 | 2 | |
78 | 2014 | Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases | YU-YUN SHAO ; MING-CHIH HO ; ANN-LII CHENG ; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 3 | 3 | |
79 | 2005 | Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients | Su W.-P.; Wen C.-C.; Hsiung C.A.; Su I.-J.; ANN-LII CHENG ; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; CHIH-HUNG HSU ; YEN-SHEN LU ; HWEI-FANG TIEN ; Chao T.-Y.; Chen L.-T.; Whang-Peng J.; PEI-JER CHEN | World Journal of Gastroenterology | 18 | 14 | |
80 | 2012 | Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer | LI-CHUN LU ; YU-YUN SHAO ; CHIH-HUNG HSU ; CHIUN HSU ; WEN-FANG CHENG ; YU-LIN LIN ; ANN-LII CHENG ; KUN-HUEI YEH | Anticancer Research | 0 | ||
81 | 2010 | Modulation of human UMP/CMP kinase affects activation and cellular sensitivity of deoxycytidine analogs | Liou J.-Y.; Lai H.-R.; CHIH-HUNG HSU ; Chang W.-L.; Hsieh M.-J.; Huang Y.-C.; Cheng Y.-C. | Biochemical Pharmacology | 10 | 10 | |
82 | 2022 | Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma | Zhu A.X.; Abbas A.R.; de Galarreta M.R.; Guan Y.; Lu S.; Koeppen H.; Zhang W.; CHIH-HUNG HSU ; He A.R.; Ryoo B.-Y.; Yau T.; Kaseb A.O.; Burgoyne A.M.; Dayyani F.; Spahn J.; Verret W.; Finn R.S.; Toh H.C.; Lujambio A.; Wang Y. | Nature Medicine | 108 | 115 | |
83 | 2020 | A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy | ZHONG-ZHE LIN ; BANG-BIN CHEN ; Hung, Yi-Ping; HUANG, PO-HSIANG ; Ying-Chun Shen ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG ; Lee, Rheun-Chuan; Chao, Yee; CHIUN HSU | Oncologist | 12 | 10 | |
84 | 2007 | Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma | CHIA-CHI LIN ; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIUN HSU ; YU-CHIEH TSAI ; Hsu W.-L.; ANN-LII CHENG ; CHIH-HUNG HSU | Anti-Cancer Drugs | 10 | 8 | |
85 | 2017 | National policies fostering hospice care increased hospice utilization and reduced the invasiveness of end-of-life care for cancer patients | YU-YUN SHAO ; Hsiue E.H.-C.; CHIH-HUNG HSU ; CHIEN-AN YAO ; Chen H.-M.; Lai M.-S.; ANN-LII CHENG | Oncologist | 21 | 17 | |
86 | 2019 | Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors | JHE-CYUAN GUO ; CHIA-CHI LIN ; Lin, Chen Yuan; MIN-SHU HSIEH ; HUNG-YANG KUO ; Lien, Ming Yu; YU-YUN SHAO ; Ta-Chen Huang ; CHIH-HUNG HSU | Anticancer research | 28 | 29 | |
87 | 2022 | Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | Doki, Yuichiro; Ajani, Jaffer A; Kato, Ken; Xu, Jianming; Wyrwicz, Lucjan; Motoyama, Satoru; Ogata, Takashi; Kawakami, Hisato; CHIH-HUNG HSU ; Adenis, Antoine; El Hajbi, Farid; Di Bartolomeo, Maria; Braghiroli, Maria I; Holtved, Eva; Ostoich, Sandra A; Kim, Hye R; Ueno, Masaki; Mansoor, Wasat; Yang, Wen-Chi; Liu, Tianshu; Bridgewater, John; Makino, Tomoki; Xynos, Ioannis; Liu, Xuan; Lei, Ming; Kondo, Kaoru; Patel, Apurva; Gricar, Joseph; Chau, Ian; Kitagawa, Yuko | The New England journal of medicine | 333 | 302 | |
88 | 2019 | Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Kato K.; Cho B.C.; Takahashi M.; Okada M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Kodani M.; Kitagawa Y. | The Lancet Oncology | 722 | 630 | |
89 | 2013 | Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κb is associated with a poor prognosis of pancreatic cancer | SHIH-HUNG YANG ; CHIH-HUNG HSU ; JEN-CHIEH LEE ; YU-WEN TIEN ; SUNG-HSIN KUO ; ANN-LII CHENG | Oncology (Switzerland) | 24 | 20 | |
90 | 2008 | OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma | Gao M.; Yeh P.Y.; YEN-SHEN LU ; CHIH-HUNG HSU ; Chen K.-F.; Lee W.-C.; Feng W.-C.; Chen C.-S.; Kuo M.-L.; ANN-LII CHENG | Cancer Research | 131 | 123 | |
91 | 2008 | Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment | ZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 5 | 1 | |
92 | 2002 | P53 Overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection | JIN-TUNG LIANG ; KUO-CHIN HUANG ; Cheng Y.-M.; Hsu H.-C.; ANN-LII CHENG ; CHIH-HUNG HSU ; KUN-HUEI YEH ; Wang S.-M.; KING-JEN CHANG | International Journal of Cancer | 66 | 57 | |
93 | 2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 117 | 112 | |
94 | 2015 | Pathological stage after neoadjuvant chemoradiation and esophagectomy superiorly predicts survival in patients with esophageal squamous cell carcinoma | CHIA-CHUN WANG ; CHIA-HSIEN CHENG ; CHIAO-LING TSAI ; JANG-MING LEE ; PEI-MING HUANG ; CHIA-CHI LIN ; CHIH-HUNG HSU ; MIN-SHU HSIEH ; YIH-LEONG CHANG ; Feng-Ming Hsu | Radiotherapy and Oncology | 9 | 8 | |
95 | 2006 | A pathway for tumor necrosis factor-α-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-κB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus | Pei Y.Y.; SUNG-HSIN KUO ; KUN-HUEI YEH ; Chuang S.-E.; CHIH-HUNG HSU ; Wen C.C.; Lin H.-I.; Gao M.; ANN-LII CHENG | Journal of Biological Chemistry | 43 | 39 | |
96 | 2022 | Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia | Cao, Y; Qin, S; Luo, S; Li, Z; Cheng, Y; Fan, Y; Sun, Y; Yin, X; Yuan, X; Li, W; Liu, T; CHIH-HUNG HSU ; Lin, X; Kim, S-B; Kojima, T; Zhang, J; Lee, S-H; Bai, Y; Muro, K; Doi, T; Bai, C; Gu, K; Pan, H-M; Bai, L; Yang, J-W; Cui, Y; Lu, W; Chen, J | ESMO open | 24 | 18 | |
97 | 2000 | Persistent severe hypocapnia and alkalemia in a 40-year-old woman | CHIA-HSUIN CHANG ; PING-HUNG KUO ; CHIH-HUNG HSU ; PAN-CHYR YANG | Chest | 8 | 6 | |
98 | 2001 | Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions | ANN-LII CHENG ; CHIH-HUNG HSU ; Lin J.-K.; Hsu M.-M.; YUNN-FANG HO ; She T.-S.; JENG-YUH KO ; Lin J.-T.; BOR-RU LIN ; MING-SHIANG WU ; Yu H.-S.; SHIOU-HWA JEE ; Chen G.-S.; Chen T.-M.; CHI-AN CHEN ; Lai M.-K.; YEONG-SHIAU PU ; MIN-HSIUNG PAN ; Wang Y.-J.; Tsai C.-C.; CHANG-YAO HSIEH | Anticancer Research | 1925 | 1695 | |
99 | 2020 | A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors | JIH-HSIANG LEE ; WEI-WU CHEN ; CHIH-HUNG HSU ; Yen Y.-H.; CHIH-HSIN YANG ; ANN-LII CHENG ; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; CHIA-CHI LIN | Investigational New Drugs | 39 | 36 | |
100 | 2014 | A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies | CHIA-CHI LIN ; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU ; Su W.-P.; KUN-HUEI YEH ; YEN-SHEN LU ; ANN-LII CHENG ; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; CHIH-HSIN YANG | British Journal of Cancer | 62 | 64 | |
101 | 2006 | Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer | Shiah H.-S.; ANN-LII CHENG ; CHIUN HSU ; CHIH-HUNG HSU ; Liu T.-W.; Chang J.-Y.; Jan C.-M.; Chao Y.; Yu W.-L.; Chuang T.-R.; Whang-Peng J.; Chen L.-T. | Journal of Gastroenterology and Hepatology (Australia) | 6 | 5 | |
102 | 2017 | Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) | Abou-Alfa G.K.; Yen C.-J.; CHIH-HUNG HSU ; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; YU-YUN SHAO ; ZHONG-ZHE LIN ; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG ; Carrasquilo J.A. | Cancer Chemotherapy and Pharmacology | 20 | 19 | |
103 | 2004 | Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma | Lu Y.-S.; CHIUN HSU ; Li C.-C.; Kuo S.-H.; KUN-HUEI YEH ; CHIH-HSIN YANG ; CHIH-HUNG HSU ; Wu C.-Y.; ANN-LII CHENG | Hepato-Gastroenterology | 14 | 13 | |
104 | 2010 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Ying-Chun Shen ; ZHONG-ZHE LIN ; PEI-JER CHEN ; YU-YUN SHAO ; Ding Y.-H.; CHIUN HSU ; ANN-LII CHENG | Journal of Hepatology | 110 | 103 | |
105 | 2019 | Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma | Ta-Chen Huang ; CHIA-CHI LIN ; Wu Y.-C.; CHIA-HSIEN CHENG ; JANG-MING LEE ; HSIU-PO WANG ; PEI-MING HUANG ; Feng-Ming Hsu ; KUN-HUEI YEH ; ANN-LII CHENG ; KAI-YUAN TZEN ; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 8 | 6 | |
106 | 1997 | A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers | KUN-HUEI YEH ; ANN-LII CHENG ; Lin M.-T.; RUEY-LONG HONG ; CHIH-HUNG HSU ; Lin J.-F.; KING-JEN CHANG ; PO-HUANG LEE ; YAO-CHANG CHEN | Anticancer Research | 32 | 27 | |
107 | 2002 | A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil | CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; CHIH-HSIN YANG ; YEN-SHEN LU ; CHIA-CHI LIN ; Bu C.-F.; KUN-HUEI YEH | Anticancer Research | 12 | 12 | |
108 | 2005 | Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.-F.; CHIUN HSU ; SUNG-HSIN KUO ; Li Jr. S.; ANN-LII CHENG | Oncology | 22 | 22 | |
109 | 2005 | Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer | KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Lin J.F.; Chao H.J.; Ta-Chen Huang ; Chung C.Y.; Chang C.S.; CHIH-HSIN YANG ; ANN-LII CHENG | British Journal of Cancer | 7 | 7 | |
110 | 2007 | A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer | CHIA-CHI LIN ; ANN-LII CHENG ; CHIH-HUNG HSU ; YEN-SHEN LU ; CHIUN HSU ; KUN-HUEI YEH ; Wu C.-Y.; CHIUN-SHENG HUANG ; CHIH-HSIN YANG | Anticancer Research | 2 | 2 | |
111 | 2007 | Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; ANN-LII CHENG ; Vogelzang N.J.; YEONG-SHIAU PU | Journal of Urology | 20 | 18 | |
112 | 2005 | Phosphorylation of cytidine, deoxycytidine, and their analog monophosphates by human UMP/CMP kinase is differentially regulated by ATP and magnesium | CHIH-HUNG HSU ; Liou J.-Y.; Dutschman G.E.; Cheng Y.-C. | Molecular Pharmacology | 27 | 24 | |
113 | 2001 | A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer | CHIA-CHI LIN ; CHIH-HUNG HSU ; Chen J.; Tsai T.-C.; ANN-LII CHENG ; YEONG-SHIAU PU | Anticancer Research | 14 | 13 | |
114 | 2013 | A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy | YU-YUN SHAO ; PO-CHIN LIANG ; YAO-MING WU ; Huang C.-C.; KAI-WEN HUANG ; CHIA-HSIEN CHENG ; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG ; ZHONG-ZHE LIN | Liver International | 15 | 15 | |
115 | 2011 | Polymorphism in epidermal growth factor receptor intron 1 predicts prognosis of patients with esophageal cancer after chemoradiation and surgery | JANG-MING LEE ; Yang S.-Y.; Yang P.-W.; CHIA-TUNG SHUN ; Wu M.-T.; CHIH-HUNG HSU ; CHIA-CHI LIN ; CHIA-HSIEN CHENG ; Wang Y.-H.; Chuang T.-H.; JIN-SHING CHEN ; HSAO-HSUN HSU ; PEI-MING HUANG ; SHUENN-WEN KUO ; Lee Y.-C. | Annals of Surgical Oncology | 21 | 19 | |
116 | 2015 | Postchemoradiotherapy pathologic stage classified by the American joint committee on the cancer staging system predicts prognosis of patients with locally advanced esophageal squamous cell carcinoma | JHE-CYUAN GUO ; Ta-Chen Huang ; CHIA-CHI LIN ; MIN-SHU HSIEH ; Chang C.-H.; PEI-MING HUANG ; JANG-MING LEE ; Feng-Ming Hsu ; CHIA-HSIEN CHENG ; HSIU-PO WANG ; KUN-HUEI YEH ; ANN-LII CHENG ; CHIH-HUNG HSU | Journal of Thoracic Oncology | 15 | 16 | |
117 | 2019 | Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma | YU-YUN SHAO ; Yong-Shi Li; Hung-Wei Hsu; Hang Lin; Han-Yu Wang; Rita Robin Wo; ANN-LII CHENG ; CHIH-HUNG HSU | Cancers | 14 | 14 | |
118 | 2021 | Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma | Hung Y.-P.; YU-YUN SHAO ; Lee J.-M.; CHIUN HSU ; CHIH-HUNG HSU ; Yang M.-H.; Chao Y. | Journal of the Chinese Medical Association | 10 | 9 | |
119 | 2002 | Pre-clinical and early-phase clinical studies of curcumin as chemopreventive agent for endemic cancers in Taiwan. | CHIH-HUNG HSU ; Chuang S.E.; Hergenhahn M.; Kuo M.L.; Lin J.K.; CHANG-YAO HSIEH ; ANN-LII CHENG | Gan to kagaku ryoho. Cancer & chemotherapy | 13 | 0 | |
120 | 2017 | Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study | LI-CHUN LU ; PEI-JER CHEN ; Yeh Y.-C.; CHIH-HUNG HSU ; Chen H.-M.; Lai M.-S.; YU-YUN SHAO ; ANN-LII CHENG | Anticancer Research | 15 | 16 | |
121 | 2022 | Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment | Chen, Ching-Tso; Feng, Yin-Hsun; Yen, Chia-Jui; Chen, San-Chi; Lin, Yun-Tzu; LI-CHUN LU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | Hepatology international | 14 | 14 | |
122 | 2012 | Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems | YU-YUN SHAO ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | British Journal of Cancer | 26 | 26 | |
123 | 2014 | Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy | YU-YUN SHAO ; CHIH-HORNG WU ; LI-CHUN LU ; Chan S.-Y.; Ma Y.-Y.; Yen F.-C.; CHIH-HUNG HSU ; ANN-LII CHENG | Journal of Hepatology | 45 | 48 | |
124 | 2007 | Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | Urology | 24 | 21 | |
125 | 2013 | Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy | WEI-WU CHEN ; CHIA-CHI LIN ; TA-CHEN HUANG ; ANN-LII CHENG ; KUN-HUEI YEH ; CHIH-HUNG HSU | Anticancer Research | 11 | 11 | |
126 | 2002 | Prognostic value of multidrug resistance 1, glutathione-S-transferase-π and p53 in advanced nasopharyngeal carcinoma treated with systemic chemotherapy | CHIH-HUNG HSU ; Chen C.-L.; RUEY-LONG HONG ; Chen K.-L.; Lin J.-F.; ANN-LII CHENG | Oncology | 31 | 25 | |
127 | 2022 | Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy | TA-CHEN HUANG ; Liang C.-W.; Li Y.-I.; GUO, JHE-CYUAN ; CHIA-CHI LIN ; Chen Y.-J.; ANN-LII CHENG ; CHIH-HUNG HSU | Journal of Cancer Research and Clinical Oncology | 2 | 2 | |
128 | 2023 | Prognostication and optimal criteria of circumferential margin involvement for esophageal cancer after chemoradiation and esophagectomy | Potdar, Ankit; KE-CHENG CHEN ; SHUENN-WEN KUO ; MONG-WEI LIN ; HSIEN-CHI LIAO ; PEI-MING HUANG ; Lee, Yi-Hsuan; Wang, Hsiu-Po; MING-LUN HAN ; CHIA-HSIEN CHENG ; CHIH-HUNG HSU ; TA-CHEN HUANG ; FENG-MING HSU ; SHAO-LUN LU ; JANG-MING LEE | Frontiers in oncology | 0 | 0 | |
129 | 2000 | Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil | KUN-HUEI YEH ; Shiou-Hwei Yeh ; CHIH-HUNG HSU ; TONG-MEI WANG ; Ma I.-F.; ANN-LII CHENG | British Journal of Cancer | 26 | ||
130 | 2013 | Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size | ZHONG-ZHE LIN ; Shau W.-Y.; CHIUN HSU ; YU-YUN SHAO ; Yeh Y.-C.; Kuo R.N.-C.; CHIH-HUNG HSU ; CHIH-HSIN YANG ; ANN-LII CHENG ; Lai M.-S. | PLoS ONE | 26 | 24 | |
131 | 2006 | Radiotherapy of classic Kaposi's sarcoma in Taiwan, an area where classic Kaposi's sarcoma is not prevalent | Huang K.-M.; CHIH-HUNG HSU ; CHIA-HSIEN CHENG ; Lai M.-K.; Jeng S.-C.; Ting L.-L.; Huang W.-T. | Anticancer Research | 10 | 7 | |
132 | 2022 | Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2 | Finn, Richard S; Yau, Thomas; CHIH-HUNG HSU ; De Toni, Enrico N; Goyal, Lipika; Galle, Peter R; Qin, ShuKui; Rao, Sujata; Sun, Fangfang; Wang, Chunxiao; Widau, Ryan C; Zhu, Andrew X | The oncologist | 5 | 7 | |
133 | 2021 | Response to Immune Checkpoint Inhibitors in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma May Be Affected by Tumor Sites | GUO, JHE-CYUAN ; Lin, Chen Yuan; CHIA-CHI LIN ; TA-CHEN HUANG ; Lien, Ming Yu; LI-CHUN LU ; HUNG-YANG KUO ; CHIH-HUNG HSU | ONCOLOGY (United States) | 1 | 1 | |
134 | 2011 | Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma | Feng-Ming Hsu ; JANG-MING LEE ; PEI-MING HUANG ; CHIA-CHI LIN ; CHIH-HUNG HSU ; YU-CHIEH TSAI ; Lee Y.-C.; CHIA-HSIEN CHENG | International Journal of Radiation Oncology Biology Physics | 38 | 36 | |
135 | 2017 | Right or left? Side selection for a totally implantable vascular access device: A randomised observational study | WEN-YING LIN ; CHIH-PENG LIN ; CHIH-HUNG HSU ; Lee, Ying Hui; Lin, Yi Ting; Hsu, Meng Chi; YU-YUN SHAO | British Journal of Cancer | 13 | 10 | |
136 | 2017 | A role of multimodality bladder-preserving therapy in patients with muscle-invasive bladder cancer plus hydronephrosis with or without pelvic nodal involvement | YUN CHIANG ; CHIA-HSIEN CHENG ; CHAO-YUAN HUANG ; YU-CHIEH TSAI ; Chia-Chi Lin ; CHIH-HUNG HSU ; ANN-LII CHENG ; YEONG-SHIAU PU | Journal of the Formosan Medical Association | 7 | 6 | |
137 | 2023 | Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma | BANG-BIN CHEN ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH ; TSUNG-HAO LIU ; YING-CHUN SHEN ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | European radiology | 17 | 13 | |
138 | 2021 | Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab | Zhu A.X.; Finn R.S.; Kang Y.-K.; Yen C.-J.; Galle P.R.; Llovet J.M.; Assenat E.; Brandi G.; Motomura K.; Ohno I.; Daniele B.; Vogel A.; Yamashita T.; CHIH-HUNG HSU ; Gerken G.; Bilbruck J.; Hsu Y.; Liang K.; Widau R.C.; Wang C.; Abada P.; Kudo M. | British Journal of Cancer | 37 | 35 | |
139 | 2012 | Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy | YU-YUN SHAO ; Huang C.-C.; Lin S.-D.; CHIH-HUNG HSU ; ANN-LII CHENG | Clinical Cancer Research | 39 | 37 | |
140 | 2015 | Serum transforming growth factor-β1 change after neoadjuvant chemoradiation therapy is associated with postoperative pulmonary complications in esophageal cancer patients undergoing combined modality therapy | SHAO-LUN LU ; Feng-Ming Hsu ; CHIAO-LING TSAI ; Wu J.-K.; JANG-MING LEE ; PEI-MING HUANG ; CHIH-HUNG HSU ; Koong A.C.; Chang D.T.; CHIA-HSIEN CHENG | International Journal of Radiation Oncology Biology Physics | 3 | 3 | |
141 | 2021 | Solving the deficit of cancer pain management skills by education programs | YU-YUN SHAO ; WEN-YING LIN ; CHIH-PENG LIN ; LI-CHUN LU ; CHIH-HUNG HSU | Supportive Care in Cancer | 2 | 2 | |
142 | 2003 | Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma | ANN-LII CHENG ; Hsiung C.A.; Su I.-J.; PEI-JER CHEN ; Chang M.-C.; Tsao C.-J.; Kao W.-Y.; Uen W.-C.; CHIH-HUNG HSU ; HWEI-FANG TIEN ; Chao T.-Y.; Chen L.-T.; Whang-Peng J. | Hepatology | 264 | 226 | |
143 | 2005 | Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and paclitaxel as first-line treatment | CHIH-HSIN YANG ; Chen M.-C.; ANN-LII CHENG ; CHIH-HUNG HSU ; KUN-HUEI YEH ; Yu Y.-C.; Whang-Peng J.; PAN-CHYR YANG | Oncology | 5 | 4 | |
144 | 2004 | Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines | Kim T.E.; Park S.-Y.; CHIH-HUNG HSU ; Dutschman G.E.; Cheng Y.-C. | Molecular Pharmacology | 11 | 10 | |
145 | 2008 | Systemic therapy for metastatic urothelial carcinoma | CHIA-CHI LIN ; CHIH-HUNG HSU ; YEONG-SHIAU PU ; Vogelzang N.J. | BJU International | 7 | 3 | |
146 | 2011 | T(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement | SUNG-HSIN KUO ; ANN-LII CHENG ; CHUNG-WU LIN ; CHIH-HUNG HSU ; MING-SHIANG WU ; KUN-HUEI YEH ; Tzeng Y.-S.; Chen L.-T. | Cancer Chemotherapy and Pharmacology | 13 | 8 | |
147 | 2018 | Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma | Chang C.-J.; YAO-HSU YANG ; Chiu C.-J.; LI-CHUN LU ; Liao C.-C.; Liang C.-W.; CHIH-HUNG HSU ; ANN-LII CHENG | International Journal of Cancer | 42 | 37 | |
148 | 2022 | Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) | Okada M.; Kato K.; Cho B.C.; Takahashi M.; Lin C.-Y.; Chin K.; Kadowaki S.; Ahn M.-J.; Hamamoto Y.; Doki Y.; Yen C.-C.; Kubota Y.; Kim S.-B.; CHIH-HUNG HSU ; Holtved E.; Xynos I.; Matsumura Y.; Takazawa A.; Kitagawa Y. | Clinical Cancer Research | 18 | 16 | |
149 | 1997 | Thymic carcinoma with autoimmune syndrome: Successful treatment with weekly infusional high-dose 5-fluorouracil and leucovorin | CHIH-HUNG HSU ; KUN-HUEI YEH ; ANN-LII CHENG | Anticancer Research | 18 | 17 | |
150 | 2022 | Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer | Doki Y.; Ueno M.; CHIH-HUNG HSU ; Oh D.-Y.; Park K.; Yamamoto N.; Ioka T.; Hara H.; Hayama M.; Nii M.; Komuro K.; Sugimoto M.; Tahara M. | Cancer Medicine | 20 | 16 | |
151 | 2021 | Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma | CHIH-HORNG WU ; PO-CHIN LIANG ; CHIH-HUNG HSU ; Chang, Fang-Tsu; YU-YUN SHAO ; TIFFANY TING-FANG SHIH | Journal of the Formosan Medical Association = Taiwan yi zhi | 21 | 17 | |
152 | 2015 | Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials | YU-YUN SHAO ; Shau, W.-Y.; Chan, S.-Y.; LI-CHUN LU ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology (Switzerland) | 29 | 29 | |
153 | 2000 | Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel | CHIH-HUNG HSU ; Chen M.-Y.; ANN-LII CHENG | Anticancer Research | 6 | 4 | |
154 | 2020 | Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours | de Bono J.; CHIA-CHI LIN ; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE ; CHIH-HUNG HSU ; CHIH-HSIN YANG ; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG | British Journal of Cancer | 19 | 17 | |
155 | 2011 | Ump/cmpk is not the critical enzyme in the metabolism of pyrimidine ribonucleotide and activation of deoxycytidine analogs in human rko cells | Hu R.; Lam W.; CHIH-HUNG HSU ; Cheng Y.-C. | PLoS ONE | 6 | 6 | |
156 | 2021 | An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma | YU-YUN SHAO ; ANN-LII CHENG ; CHIH-HUNG HSU | Oncologist | 7 | 5 | |
157 | 2021 | The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma | Hung Y.-P.; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; Lee J.-M.; Yang M.-H.; Chao Y. | Journal of the Formosan Medical Association | 4 | 4 | |
158 | 1997 | Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers | CHIH-HUNG HSU ; KUN-HUEI YEH ; Chen L.-T.; Liu J.M.; Jan C.-M.; Lin J.-T.; YAO-CHANG CHEN ; ANN-LII CHENG | Oncology (Switzerland) | 60 | 51 | |
159 | 2008 | Weekly 24-hour infusional 5-fluorouracil as initial treatment for advanced gastric cancer with acute disseminated intravascular coagulation | TA-CHEN HUANG ; KUN-HUEI YEH ; ANN-LII CHENG ; CHIH-HUNG HSU | Anticancer Research | 15 | 9 | |
160 | 2006 | Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; ANN-LII CHENG ; Chen J.; Vogelzang N.J.; YEONG-SHIAU PU | Cancer | 24 | 24 | |
161 | 2004 | Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract | CHIUN HSU ; Ying-Chun Shen ; CHIH-HSIN YANG ; KUN-HUEI YEH ; YEN-SHEN LU ; CHIH-HUNG HSU ; Liu H.-T.; Li C.-C.; Chen J.-S.; Wu C.-Y.; ANN-LII CHENG | British Journal of Cancer | 42 | 40 | |
162 | 2007 | Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial | CHIA-CHI LIN ; CHIH-HUNG HSU ; Hour T.-C.; ANN-LII CHENG ; CHAO-YUAN HUANG ; KUO-HOW HUANG ; Chen J.; YEONG-SHIAU PU | Urologic Oncology: Seminars and Original Investigations | 6 | 6 | |
163 | 2014 | β-Catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma | LI-CHUN LU ; YU-YUN SHAO ; Lee Y.-H.; MIN-SHU HSIEH ; Hsiao C.-H.; Lin H.-H.; HSIANG-FONG KAO ; Ma Y.-Y.; Yen F.-C.; ANN-LII CHENG ; CHIH-HUNG HSU | Oncology (Switzerland) | 25 | 24 |